Digbi Health preprint shows IBS relief in 16,000-member study
Digbi Health has posted a large-scale real-world study on medRxiv showing that its precision biology programme reduced IBS symptom severity scores in a cohort of nearly 16,000 members. The Mountain View-based digital health company said the findings were corrected for regression to the mean, a common source of inflation in single-arm studies of this type.
The analysis covered 15,933 members who completed a baseline assessment on the IBS Symptom Severity Scale, a validated 500-point instrument. After statistical correction, members showed an average 47.7-point reduction in score at 12 weeks. Among the subset with symptomatic IBS at baseline, 53.8% achieved a reduction of at least 50 points, the threshold the authors describe as clinically meaningful.
What the data show
Response rates tracked closely with baseline severity. Among members categorised as mild cases, 41% met the response threshold; in moderate cases that rose to 59%; and among severe cases, 71% responded. The authors report consistent improvement across age, sex, income, and ethnicity subgroups, and say results were not explained by concurrent medication use or by members starting a GLP-1 drug during follow-up.
An intra-member analysis found that tracking nutrient-dense meals correlated with lower symptom scores, while weight change showed no association. The company argues this points to food quality matched to individual biology as the operative variable, rather than weight loss per se.
Ranjan Sinha, founder and chief executive, said the programme "replaces the guesswork" of conventional IBS management. "When we read a person's genes, gut microbiome and glucose response, we address what is actually driving their symptoms, and the relief holds up under the most conservative evaluation," he said.
Digbi's gut microbiome panel sequences the genes of a member's gut bacteria, including species that produce dipeptidyl peptidase enzymes involved in GLP-1 degradation, linking its GI care pathway to its metabolic care offering. The company sells to employers and health plans through a single contract covering metabolic, gastrointestinal, inflammatory, and hormonal care.
Market context and limitations
The IBS digital therapeutics market has attracted growing interest from payers and employers seeking to reduce gastroenterology referral rates and pharmacy spend. Several companies, including microbiome-focused startups and broader gut-health platforms, are competing for employer contracts with programmes that combine dietary coaching, microbiome testing, and symptom tracking. Digbi's study size is unusually large for a real-world digital health dataset, which is a meaningful differentiator in a space where evidence quality is frequently questioned.
There are, however, important caveats. The study is a preprint and has not yet been peer reviewed. It is a single-arm observational study; there is no randomised control group, and the regression-to-the-mean correction, while standard practice, is no substitute for a controlled trial design. The 1,339 symptomatic members used for the response-rate calculation represent a fraction of the 15,933 enrolled, and the basis for that subsetting is not fully explained in the press release. Investors and clinical buyers will want to see the full preprint methodology and, ultimately, randomised evidence before drawing firm conclusions about clinical efficacy. The company says it has published peer-reviewed actuarial claims studies on cost reduction, which may provide supporting evidence for payer conversations ahead of trial-level data.